Recovering Testosterone After Hormone Therapy for #ProstateCancer | [Video]

Embark Clinical Trial: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2303974

Donate to PCRI: https://pcri.org/donate/
For more information, visit https://pcri.org

0:52 When is it right for a patient with a stable PSA to discontinue hormone therapy?
3:36 What are the upsides to discontinuing treatment and regaining testosterone?
4:43 How can a patient feel safe from recurrence after discontinuing hormone therapy?
8:03 How soon after promising treatment response should a treatment be discontinued?
9:42 How effective is treating a metastasis with spot radiation and forgoing hormone therapy?
10:52 At what PSA level would a patient be urged to go back on treatment?
11:26 Is testosterone replacement available to patients with stable PSA’s following treatment?
13:21 How can patients navigate the decision to end treatment with their physician/caregiver?
14:19 Alex’s conclusions

Don’t know your stage? Take the quiz: visit http://www.prostatecancerstaging.org

To learn more about prostate cancer, visit http://www.pcri.org

Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: https://pcri.org/join

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.